[Benoxaprofen in the treatment of spondylosis and spondylarthrosis (author's transl)].
An open clinical trial of 4 weeks included 32 patients with spondylosis and spondylarthrosis diagnosed on the average about 10 years previously. The non-steroid antirheumatic benoxaprofen was used alone in a dosage of a 1 x 600 mg tablet daily. The treatment had a marked influence on the clinical picture in the form of reduction of the pain at the beginning of movement, and of pains at night or on pressure. The extent of the night pains was already reduced to a statistically significant degree (alpha less than or equal to 0.05) after 1 week and remained so during the course of the treatment. Three patients had to discontinue the treatment prematurely because of side effects (photosensitivity in 2 and gastric intolerance in 1). No negative influence on clinical chemical or hematological parameters was seen in any of the patients.
D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D001583:Benzoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010787:Photosensitivity Disorders / Q000139:chemically induced; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*; D013122:Spinal Diseases / Q000188:drug therapy*
D001583:Benzoxazoles; D011422:Propionates; C011677:benoxaprofen; D000082:Acetaminophen
Benoxaprofen in der Behandlung von spondylosen und Spondylarthrosen.